Sign in
Taking peopleNo phase

A Cohort Study of the Efficacy and Safety of Biologics in Patients With ABPA

Key facts

Who runs it
Qianfoshan Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
50 people, planned
Started
31 Jan 2025
Expected to end
31 Dec 2028
Type of study
Observational, 2 groups
Treatments tested
  • Biologic Agent
Record updated
17 April 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (12)Hide the full registry criteria

Who can take part

  • Meet the diagnostic criteria of allergic bronchopulmonary aspergillosis, according to the ISHAM guidelines for the diagnosis and treatment of allergic bronchopulmonary aspergillosis (2024 revision)
  • The underlying disease was bronchial asthma, and it was severe bronchial asthma
  • Have had an acute asthma attack in the past year. Acute exacerbation of asthma is defined as the sudden onset of wheezing, shortness of breath, cough, chest tightness and other symptoms beyond the definition of uncontrolled asthma, or the aggravation of the original symptoms, and is characterized by decreased expiratory flow, often induced by exposure to allergens, irritants or respiratory tract infection
  • Blood eosinophil count ≥150 cells /μL
  • Age ≥ 18 years old

Who cannot take part

  • The underlying diseases were chronic obstructive pulmonary disease and bronchiectasis
  • Known allergic history to biological agents
  • Human immunodeficiency virus infection, active pulmonary tuberculosis or pulmonary malignant tumor
  • Complicated with other diseases requiring long-term systemic use of glucocorticoids or immunosuppressants (such as autoimmune diseases)
  • Any other conditions considered by the investigator to preclude participation in the study (e.g., nonadherence, predicted survival <1 year, or severe mental illness that prevented cooperation)
  • Pregnant or lactating women
  • Currently participating in other interventional clinical research

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To evaluate the efficacy and safety of biological agents in patients with allergic bronchopulmonary aspergillosis.

The 2 groups in the trial

  • Observation group: on the basis of the original standard drug treatment, combined with biological ag

    Treatment: Biologic Agent

  • The control group only received standard drug treatment (oral glucocorticoids with or without oral a

    The standard medical regimen was oral prednisone (0.5mg/Kg/ day for 4 weeks, 0.25mg/Kg/ day for 4 weeks, followed by 0.125mg/Kg/ day for 4 weeks, followed by a reduction of 5mg every 2 weeks until discontinuation) with or without oral voriconazole (200mg bid, 1 hour before or after meals).

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Multicenter, Observational Cohort Study on the Efficacy and Safety of Biological Agents in Patients With Allergic Bronchopulmonary Aspergillosis
Criteria questions
Built from NCT07362693, who can take part
Record updated
17 April 2026